Therefore, double-targeting of the BCR/NF-κB cascade at a proximal and a distal point might lead to more lasting suppression of this critical signaling backbone—and is not necessarily restricted to ABC patients. The gene discussed is BCR; the disease is aneurysmal bone cyst.